Table 5.
Percentages of patients achieving a best response of VGPR or better to lenalidomide-bortezomib-dexamethasone and estimated 18-month PFS rates after lenalidomide-bortezomib-dexamethasone with/without ASCT, according to disease stage, baseline β2-microglobulin, baseline albumin, and presence of baseline cytogenetic abnormalities
| Characteristic/value | n | Response of VGPR or better, n (%) | Estimated 18-month PFS, % (95% CI) |
|---|---|---|---|
| Baseline characteristic | |||
| ISS disease stage | |||
| I | 29 | 21 (72) | 89 (70-96) |
| II/III | 37 | 23 (62) | 65 (47-78) |
| Durie-Salmon disease stage | |||
| I | 22 | 12 (55) | 82 (59-93) |
| II/III | 44 | 32 (73) | 72 (56-83) |
| β2-microglobulin, mg/L | |||
| < 3.5 | 44 | 32 (73) | 77 (61-87) |
| ≥ 3.5 | 22 | 12 (55) | 73 (49-87) |
| Albumin, g/dL | |||
| < 3.5 | 24 | 17 (71) | 63 (40-78) |
| ≥ 3.5 | 42 | 27 (64) | 83 (67-91) |
| Cytogenetics present | |||
| Abnormal metaphase cytogenetics | |||
| Yes | 6 | 5 (83) | 83 (27-97) |
| No | 60 | 39 (65) | 75 (62-84) |
| Del 13/13q by FISH | |||
| Yes | 24 | 18 (75) | 79 (57-91) |
| No | 27 | 16 (59) | 65 (43-80) |
| Del 17p by FISH | |||
| Yes | 5 | 3 (60) | 100 |
| No | 45 | 30 (67) | 68 (52-80) |
| t(4;14) by FISH | |||
| Yes | 2 | 2 (100) | 100 |
| No | 39 | 24 (62) | 63 (46-77) |
| t(11;14) by FISH | |||
| Yes | 11 | 7 (64) | 73 (37-90) |
| No | 40 | 28 (70) | 72 (55-83) |
| Del 17p and/or t(4;14) by FISH | |||
| Yes | 6 | 4 (67) | 100 |
| No | 44 | 29 (66) | 68 (51-79) |
FISH indicates fluorescence in situ hybridization; ISS, International Staging System; PFS, progression-free survival after lenalidomide-bortezomib-dexamethasone with/without transplantation; and VGPR, very good partial response.